In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020Shots:Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…